105 related articles for article (PubMed ID: 23063327)
1. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
Ghaleiha A; Entezari N; Modabbernia A; Najand B; Askari N; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Feb; 47(2):175-80. PubMed ID: 23063327
[TBL] [Abstract][Full Text] [Related]
2. Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial.
Shokrani M; Askari S; Eissazade N; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
BMC Psychiatry; 2023 Sep; 23(1):686. PubMed ID: 37735631
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of transcranial direct current stimulation as add-on therapy to fluoxetine in obsessive-compulsive disorder: a randomized, double-blind, sham-controlled, clinical trial.
Yoosefee S; Amanat M; Salehi M; Mousavi SV; Behzadmanesh J; Safary V; Yoonesi A; Salehi B
BMC Psychiatry; 2020 Nov; 20(1):570. PubMed ID: 33256659
[TBL] [Abstract][Full Text] [Related]
4. Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial.
Tilaki EH; Hasanzadeh A; Shalbafan M; Moghaddam HS; Shamabadi A; Boroon M; Akhondzadeh S
Clin Neuropharmacol; 2023 Sep-Oct 01; 46(5):175-180. PubMed ID: 37747999
[TBL] [Abstract][Full Text] [Related]
5. Tolcapone in obsessive-compulsive disorder: a randomized double-blind placebo-controlled crossover trial.
Grant JE; Hook R; Valle S; Chesivoir E; Chamberlain SR
Int Clin Psychopharmacol; 2021 Sep; 36(5):225-229. PubMed ID: 34310432
[TBL] [Abstract][Full Text] [Related]
6. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).
Haghighi M; Jahangard L; Mohammad-Beigi H; Bajoghli H; Hafezian H; Rahimi A; Afshar H; Holsboer-Trachsler E; Brand S
Psychopharmacology (Berl); 2013 Aug; 228(4):633-40. PubMed ID: 23525525
[TBL] [Abstract][Full Text] [Related]
7. An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder.
Bakhla AK; Verma V; Soren S; Sarkhel S; Chaudhury S
Ind Psychiatry J; 2013 Jul; 22(2):149-52. PubMed ID: 25013317
[TBL] [Abstract][Full Text] [Related]
8. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
Häge A; Banaschewski T; Buitelaar JK; Dijkhuizen RM; Franke B; Lythgoe DJ; Mechler K; Williams SC; Dittmann RW;
Trials; 2016 Mar; 17(1):141. PubMed ID: 26983548
[TBL] [Abstract][Full Text] [Related]
9. Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial.
Modarresi A; Sayyah M; Razooghi S; Eslami K; Javadi M; Kouti L
Pharmacopsychiatry; 2018 Nov; 51(6):263-269. PubMed ID: 29100251
[TBL] [Abstract][Full Text] [Related]
10. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.
Paydary K; Akamaloo A; Ahmadipour A; Pishgar F; Emamzadehfard S; Akhondzadeh S
J Clin Pharm Ther; 2016 Apr; 41(2):214-9. PubMed ID: 26931055
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
[TBL] [Abstract][Full Text] [Related]
12. Glutamatergic agents for OCD and related disorders.
Pittenger C
Curr Treat Options Psychiatry; 2015 Sep; 2(3):271-283. PubMed ID: 26301176
[TBL] [Abstract][Full Text] [Related]
13. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.
Pittenger C; Bloch MH; Wasylink S; Billingslea E; Simpson R; Jakubovski E; Kelmendi B; Sanacora G; Coric V
J Clin Psychiatry; 2015 Aug; 76(8):1075-84. PubMed ID: 26214725
[TBL] [Abstract][Full Text] [Related]
14. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.
Heidari M; Zarei M; Hosseini SM; Taghvaei R; Maleki H; Tabrizi M; Fallah J; Akhondzadeh S
Int Clin Psychopharmacol; 2014 Nov; 29(6):344-50. PubMed ID: 24850229
[TBL] [Abstract][Full Text] [Related]
15. Obsessive compulsive disorder and the glutamatergic system.
Kariuki-Nyuthe C; Gomez-Mancilla B; Stein DJ
Curr Opin Psychiatry; 2014 Jan; 27(1):32-7. PubMed ID: 24270485
[TBL] [Abstract][Full Text] [Related]
16. Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder.
Marinova Z; Chuang DM; Fineberg N
Curr Neuropharmacol; 2017; 15(7):977-995. PubMed ID: 28322166
[TBL] [Abstract][Full Text] [Related]
17. Glutamate modulators in the treatment of obsessive-compulsive disorder.
Pittenger C
Psychiatr Ann; 2015 Jun; 45(6):308-315. PubMed ID: 26236057
[TBL] [Abstract][Full Text] [Related]
18. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.
Arabzadeh S; Shahhossenie M; Mesgarpour B; Rezaei F; Shalbafan MR; Ghiasi Z; Akhondzadeh S
Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28485008
[TBL] [Abstract][Full Text] [Related]
19. Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach.
Grados MA; Specht MW; Sung HM; Fortune D
Expert Opin Drug Discov; 2013 Dec; 8(12):1515-27. PubMed ID: 24147578
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
